Medications targeting dopamine receptors for managing schizophrenia and bipolar disorders, supplied by pharmaceutical firms to psychiatric hospitals, mental health clinics, and retail pharmacies. Healthcare providers procure these through specialized distribution networks for inpatient and outpatient treatment.